Figure 4 | Scientific Reports

Figure 4

From: Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma

Figure 4

(A) A Kaplan–Meier curve for progression free survival (PFS) rate for 44 patients with a one-year PFS of 54.7% (95%CI, 39.0–69.4). (B) PFS rate in the subgroups was 78.0% (53.9–91.5), 40.0% (12.3–87.7) and 20.0% (6.6–47.0) (p < 0.0001, log-rank) according to methionine uptake status and temozolomide finalization or continuation. For more details, see Results section.

Back to article page